Showing results (101-110 of 219) with videos related to
Sort By:
Pageof 22
Cancer|October 23, 2025
A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lensHagop M Kantarjian, Gautam Borthakur, Naval Daver, et al.Cancer|February 13, 2026
Clinical, genetic, and familial features of POT1 tumor predisposition syndromeCourtney D DiNardo, Jennifer Croden, Hiam M Abdel-Salam, et al.Cancer|December 15, 2005
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimensWilliam Wierda, Susan O'brien, Stefan Faderl, et al.American Journal of Hematology|October 14, 2017
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitorsAhmad Alhuraiji, Hagop Kantarjian, Prajwal Boddu, et al.American Journal of Hematology|April 22, 2011
Prediction model for mortality after intracranial hemorrhage in patients with leukemiaFarshid Dayyani, Sarah Schellhorn Mougalian, Kiran Naqvi, et al.Molecular Cancer Research : MCR|January 29, 2017
Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 ComplexUri Rozovski, David M Harris, Ping Li, et al.Journal of Surgical Oncology|August 29, 2024
Comparison of a risk calculator with frailty indices in patients undergoing lung cancer resectionDominic J Vitello, Charles D Logan, Norah N Zaza, et al.Journal of Surgical Oncology|October 10, 2024
Comparison of a Risk Calculator With Frailty Indices in Patients Undergoing Lung Cancer ResectionDominic J Vitello, Charles D Logan, Norah N Zaza, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaMichael J Keating, Susan O'Brien, Maher Albitar, et al.Molecular Cancer Research : MCR|May 20, 2014
STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosisPing Li, David Harris, Zhiming Liu, et al.Pageof 22